CoChat
Sign Up
Cited by 111

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9

LaFountaine, Justin S., Fathe, Kristin, Smyth, Hugh D.C.·2015·International Journal of Pharmaceutics
DOI 10.1016/j.ijpharm.2015.08.029
Open this paper in CoChat — free account

Abstract

In recent years, several new genome editing technologies have been developed. Of these the zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the CRISPR/Cas9 RNA-guided endonuclease system are the most widely described. Each of these technologies utilizes restriction enzymes to introduce a DNA double stranded break at a targeted location with the guide of homologous binding proteins or RNA. Such targeting is viewed as a significant advancement compared to current gene therapy methods that lack such specificity. Proof-of-concept studies have been performed to treat multiple disorders, including in vivo experiments in mammals and even early phase human trials. Careful consideration and investigation of delivery strategies will be required so that the therapeutic potential for gene editing is achieved. In this review, the mechanisms of each of these gene editing technologies and evidence of therapeutic potential will be briefly described and a comprehensive list of past studies will be provided. The pharmaceutical approaches of each of these technologies are discussed along with the current delivery obstacles. The topics and information reviewed herein provide an outline of the groundbreaking research that is being performed, but also highlights the potential for progress yet to be made using these gene editing technologies.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ijpharm.2015.08.029

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 129

  1. Ahi, 2011, Adenoviral vector immunity: its implications and circumvention strategies, Curr. Gene Ther., 11, 307, 10.2174/156652311796150372 · DOI · Paper page
  2. Almofti, 2003, Cationic liposome-mediated gene delivery: biophysical study and mechanism of internalization, Arch. Biochem. Biophys., 410, 246, 10.1016/S0003-9861(02)00725-7 · DOI
  3. Bach, 2014, Evaluation of novel design strategies for developing zinc finger nucleases tools for treating human diseases, Biotechnol. Res. Int., 2014, 1, 10.1155/2014/970595 · DOI
  4. Bacman, 2013, Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs, Nat. Med., 19, 1111, 10.1038/nm.3261 · DOI · Paper page
  5. Basu, 2005, Artificial and engineered chromosomes: non-integrating vectors for gene therapy, Trends Mol. Med., 11, 251, 10.1016/j.molmed.2005.03.006 · DOI
  6. Bibikova, 2003, Enhancing gene targeting with designed zinc finger nucleases, Science, 300, 764, 10.1126/science.1079512 · DOI
  7. Bitinaite, 1998, FokI dimerization is required for DNA cleavage, Proc. Natl. Acad. Sci. U. S. A., 95, 10570, 10.1073/pnas.95.18.10570 · DOI
  8. Bloom, 2013, Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases, Mol. Ther., 21, 1889, 10.1038/mt.2013.170 · DOI · Paper page
  9. Boch, 2009, Breaking the code of DNA binding specificity of TAL-type III effectors, Science, 326, 1509, 10.1126/science.1178811 · DOI · Paper page
  10. Bradley, 1984, Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines, Nature, 309, 255, 10.1038/309255a0 · DOI
  11. Bzymek, 2001, Instability of repetitive DNA sequences: the role of replication in multiple mechanisms, Proc. Natl. Acad. Sci. U. S. A., 98, 8319, 10.1073/pnas.111008398 · DOI
  12. Cai, 2014, Targeted genome editing tools for disease modeling and gene therapy, Curr. Gene Ther., 14, 2, 10.2174/156652321402140318165450 · DOI
  13. Cai, 2014, Targeted genome editing by lentiviral protein transduction of zinc-finger and TAL-effector nucleases, eLife, 3, e01911, 10.7554/eLife.01911 · DOI
  14. Camenisch, 1998, Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight, Eur. J. Pharm. Sci., 6, 317, 10.1016/S0928-0987(97)10019-7 · DOI
  15. Capecchi, 1989, Altering the genome by homologous recombination, Science, 244, 1288, 10.1126/science.2660260 · DOI
  16. Cavazzana-Calvo, 2000, Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease, Science, 288, 669, 10.1126/science.288.5466.669 · DOI
  17. Chan, 2006, Mitochondria: dynamic organelles in disease, aging, and development, Cell, 125, 1241, 10.1016/j.cell.2006.06.010 · DOI · Paper page
  18. Check, 2002, Gene therapy: a tragic setback, Nature, 420, 116, 10.1038/420116a · DOI
  19. Chen, 2015, Disruption of microRNA-21 by TALEN leads to diminished cell transformation and increased expression of cell-environment interaction genes, Cancer Lett., 356, 506, 10.1016/j.canlet.2014.09.034 · DOI
  20. Chen, 2014, An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases, Mol. Ther., 22, 303, 10.1038/mt.2013.212 · DOI · Paper page
  21. Chen, 2013, A large-scale in vivo analysis reveals that TALENs are significantly more mutagenic than ZFNs generated using context-dependent assembly, Nucleic Acids Res., 41, 2769, 10.1093/nar/gks1356 · DOI
  22. Cho, 2014, Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases, Genome Res., 24, 132, 10.1101/gr.162339.113 · DOI · Paper page
  23. Cornu, 2008, DNA-binding specificity is a major determinant of the activity and toxicity of zinc-finger nucleases, Mole. Ther., 16, 352, 10.1038/sj.mt.6300357 · DOI
  24. Cradick, 2013, CRISPR/Cas9 systems targeting beta-globin and CCR5 genes have substantial off-target activity, Nucleic Acids Res., 41, 9584, 10.1093/nar/gkt714 · DOI · Paper page
  25. Cross, 2006, Gene therapy for cancer treatment: past, present and future, Clin. Med. Res., 4, 218, 10.3121/cmr.4.3.218 · DOI
  26. Ding, 2013, Liver in a dish, Cell Res., 23, 1242, 10.1038/cr.2013.117 · DOI
  27. Ding, 2014, Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing, Circ. Res., 115, 488, 10.1161/CIRCRESAHA.115.304351 · DOI · Paper page
  28. Dong, 2015, Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication, Antiviral Res., 118, 110, 10.1016/j.antiviral.2015.03.015 · DOI
  29. Ellis, 2013, Zinc-finger nuclease-mediated gene correction using single AAV vector transduction and enhancement by Food and Drug Administration-approved drugs, Gene Ther., 20, 35, 10.1038/gt.2011.211 · DOI
  30. Fadel, 2014, TALEN knockout of the PSIP1 gene in human cells: analyses of HIV-1 replication and allosteric integrase inhibitor mechanism, J. Virol., 88, 9704, 10.1128/JVI.01397-14 · DOI
  31. Feng, 2014, Targeting Cdk 11 in osteosarcoma cells using the CRISPR-cas9 system, J. Orthop. Res., 33, 199, 10.1002/jor.22745 · DOI
  32. Filareto, 2013, An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells, Nat. Commun., 4, 1549, 10.1038/ncomms2550 · DOI
  33. Fischer, 2010, 20 years of gene therapy for SCID, Nat. Immunol., 11, 457, 10.1038/ni0610-457 · DOI
  34. Fonseca, 2009, Recent advances in the use of cell-penetrating peptides for medical and biological applications, Adv. Drug Deliv. Rev., 61, 953, 10.1016/j.addr.2009.06.001 · DOI
  35. Fujikawa, 2006, Suppression of defense response in plants by the avrBs3/pthA gene family of Xanthomonas spp, Mol. Plant Microbe Interact., 19, 342, 10.1094/MPMI-19-0342 · DOI
  36. Gaj, 2013, ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering, Trends Biotechnol., 31, 397, 10.1016/j.tibtech.2013.04.004 · DOI · Paper page
  37. Gellhaus, 2010, Fate of recombinant adeno-associated viral vector genomes during DNA double-strand break-induced gene targeting in human cells, Hum. Gene Ther., 21, 543, 10.1089/hum.2009.167 · DOI
  38. Giacca, 2012, Virus-mediated gene delivery for human gene therapy, J. Control. Release, 161, 377, 10.1016/j.jconrel.2012.04.008 · DOI · Paper page
  39. Ginn, 2013, Gene therapy clinical trials worldwide to 2012—an update, J. Gene Med., 15, 65, 10.1002/jgm.2698 · DOI
  40. Gordon, 1981, Integration and stable germ line transmission of genes injected into mouse pronuclei, Science, 214, 1244, 10.1126/science.6272397 · DOI
  41. Handel, 2009, Expanding or restricting the target site repertoire of zinc-finger nucleases: the inter-domain linker as a major determinant of target site selectivity, Mol. Ther., 17, 104, 10.1038/mt.2008.233 · DOI
  42. Hefferin, 2005, Mechanism of DNA double-strand break repair by non-homologous end joining, DNA Repair, 4, 639, 10.1016/j.dnarep.2004.12.005 · DOI
  43. Holkers, 2014, Adenoviral vector DNA for accurate genome editing with engineered nucleases, Nat. Methods, 11, 1051, 10.1038/nmeth.3075 · DOI · Paper page
  44. Holt, 2010, Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo, Nat. Biotechnol., 28, 839, 10.1038/nbt.1663 · DOI · Paper page
  45. Hu, 2014, RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection, Proc. Natl. Acad. Sci. U. S. A., 111, 11461, 10.1073/pnas.1405186111 · DOI · Paper page
  46. Hu, 2014, TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy, J. Clin. Invest., 125, 425, 10.1172/JCI78206 · DOI
  47. Hu, 2014, Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells, BioMed Res. Int., 2014, 612823, 10.1155/2014/612823 · DOI
  48. Hurt, 2003, Highly specific zinc finger proteins obtained by directed domain shuffling and cell-based selection, Proc. Natl. Acad. Sci. U. S. A., 100, 12271, 10.1073/pnas.2135381100 · DOI
  49. Jiang, 2013, Translating dosage compensation to trisomy 21, Nature, 500, 296, 10.1038/nature12394 · DOI
  50. Jung, 2012, Concise review: Induced pluripotent stem cell-derived mesenchymal stem cells: progress toward safe clinical products, Stem Cells, 30, 42, 10.1002/stem.727 · DOI
  51. Kabadi, 2014, Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector, Nucleic Acids Res., 42, e147, 10.1093/nar/gku749 · DOI · Paper page
  52. Kaiser, 2003, Gene therapy. Seeking the cause of induced leukemias in X-SCID trial, Science, 299, 495, 10.1126/science.299.5606.495 · DOI
  53. Kennedy, 2015, Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease, Virology, 476, 196, 10.1016/j.virol.2014.12.001 · DOI · Paper page
  54. Kim, 2014, A guide to genome engineering with programmable nucleases, Nat. Rev. Genet., 15, 321, 10.1038/nrg3686 · DOI
  55. Kinali, 2009, Local restoration of dystrophin expression with the morpholino oligomer AVI-465 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study, Lancet Neurol., 8, 918, 10.1016/S1474-4422(09)70211-X · DOI
  56. Lappalainen, 1994, Comparison of cell proliferation and toxicity assays using two cationic liposomes, Pharm. Res., 11, 1127, 10.1023/A:1018932714745 · DOI
  57. Lee, 2012, Correction of the deltaF508 mutation in the cystic fibrosis transmembrane conductance regulator gene by zinc-finger nuclease homology-directed repair, BioRes. Open Access, 1, 99, 10.1089/biores.2012.0218 · DOI
  58. Li, 2014, Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9, Stem Cell Rep., 4, 143, 10.1016/j.stemcr.2014.10.013 · DOI · Paper page
  59. Lieber, 2003, Mechanism and regulation of human non-homologous DNA end-joining, Nat. Rev. Mol. Cell Biol., 4, 712, 10.1038/nrm1202 · DOI
  60. Lin, 2014, The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo, Mol. Ther., 3, e186
  61. Liu, 2014, Cell-penetrating peptide-mediated delivery of TALEN proteins via bioconjugation for genome engineering, PLoS One, 9, e85755, 10.1371/journal.pone.0085755 · DOI
  62. Liu, 2014, CRISPR-Cas system: a powerful tool for genome engineering, Plant Mol. Biol., 85, 209, 10.1007/s11103-014-0188-7 · DOI
  63. Liu, 2015, Inhibition of hepatitis B virus by CRISPR/Cas9 system via targeting the conserved regions of viral genome, J. Gen. virol.
  64. Long, 2014, Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA, Science, 345, 1184, 10.1126/science.1254445 · DOI · Paper page
  65. Ma, 2013, Transcription activator-like effector nuclease (TALEN)-mediated gene correction in integration-free beta-thalassemia induced pluripotent stem cells, J. Biol. Chem., 288, 34671, 10.1074/jbc.M113.496174 · DOI
  66. Mae, 2006, Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery, Curr. Opin. Pharmacol., 6, 509, 10.1016/j.coph.2006.04.004 · DOI
  67. Mali, 2013, RNA-guided human genome engineering via Cas9, Science, 339, 823, 10.1126/science.1232033 · DOI · Paper page
  68. Matrai, 2010, Recent advances in lentiviral vector development and applications, Mol. Ther., 18, 477, 10.1038/mt.2009.319 · DOI
  69. Matsubara, 2014, Transcription activator-like effector nuclease-mediated transduction of exogenous gene into IL2RG locus, Sci. Rep., 4, 5043, 10.1038/srep05043 · DOI
  70. McNeer, 2015, Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium, Nat. Commun., 6, 6952, 10.1038/ncomms7952 · DOI
  71. Metzger, 2011, Single-strand nicks induce homologous recombination with less toxicity than double-strand breaks using an AAV vector template, Nucleic Acids Res., 39, 926, 10.1093/nar/gkq826 · DOI
  72. Miller, 2007, An improved zinc-finger nuclease architecture for highly specific genome editing, Nat. Biotechnol., 25, 778, 10.1038/nbt1319 · DOI · Paper page
  73. Minczuk, 2006, Sequence-specific modification of mitochondrial DNA using a chimeric zinc finger methylase, Proc. Natl. Acad. Sci. U. S. A., 103, 19689, 10.1073/pnas.0609502103 · DOI · Paper page
  74. Moscou, 2009, A simple cipher governs DNA recognition by TAL effectors, Science, 326, 1501, 10.1126/science.1178817 · DOI
  75. Mussolino, 2011, A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity, Nucleic Acids Res., 39, 9283, 10.1093/nar/gkr597 · DOI · Paper page
  76. Niu, 2014, Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos, Cell, 156, 836, 10.1016/j.cell.2014.01.027 · DOI · Paper page
  77. Olson, 1982, Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes, Eur. J. Cancer Clin. Oncol., 18, 167, 10.1016/0277-5379(82)90060-8 · DOI
  78. Osborn, 2013, TALEN-based gene correction for epidermolysis bullosa, Mol. Ther., 21, 1151, 10.1038/mt.2013.56 · DOI · Paper page
  79. Ousterout, 2015, Correction of dystrophin expression in cells from duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger Nucleases, Mol. Ther., 23, 523, 10.1038/mt.2014.234 · DOI
  80. Ousterout, 2013, Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients, Mol. Ther., 21, 1718, 10.1038/mt.2013.111 · DOI
  81. Park, 2014, Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs, Proc. Natl. Acad. Sci. U. S. A., 111, 9253, 10.1073/pnas.1323941111 · DOI
  82. Rahman, 2013, The nontoxic cell cycle modulator indirubin augments transduction of adeno-associated viral vectors and zinc-finger nuclease-mediated gene targeting, Hum. Gene Ther., 24, 67, 10.1089/hum.2012.168 · DOI
  83. Ramanan, 2015, CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus, Sci. Rep., 5, 10833, 10.1038/srep10833 · DOI
  84. Ran, 2013, Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity, Cell, 154, 1380, 10.1016/j.cell.2013.08.021 · DOI · Paper page
  85. Rio, 2014, Targeted gene therapy and cell reprogramming in Fanconi anemia, EMBO Mol. Med., 6, 835, 10.15252/emmm.201303374 · DOI
  86. Ru, 2013, Targeted genome engineering in human induced pluripotent stem cells by penetrating TALENs, Cell Regen., 2, 5, 10.1186/2045-9769-2-5 · DOI
  87. Samson, 1996, Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene, Nature, 382, 722, 10.1038/382722a0 · DOI
  88. Sargent, 2014, Nuclease-mediated double-strand break (DSB) enhancement of small fragment homologous recombination (SFHR) gene modification in human-induced pluripotent stem cells (hiPSCs), Methods Mol. Biol., 1114, 279, 10.1007/978-1-62703-761-7_18 · DOI
  89. Sebastiano, 2011, In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases, Stem Cells, 29, 1717, 10.1002/stem.718 · DOI
  90. Seeger, 2014, Targeting hepatitis B virus with CRISPR/Cas9, Mol. Ther. Nucleic Acids, 3, e216, 10.1038/mtna.2014.68 · DOI · Paper page
  91. Senis, 2014, CRISPR/Cas-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox, Biotechnol. J., 9, 1402, 10.1002/biot.201400046 · DOI
  92. Smidler, 2013, Targeted mutagenesis in the malaria mosquito using TALE nucleases, PLoS One, 8, e74511, 10.1371/journal.pone.0074511 · DOI
  93. Smith, 2015, Efficient and allele-specific genome editing of disease loci in human iPSCs, Mol. Ther., 23, 570, 10.1038/mt.2014.226 · DOI
  94. Soldner, 2011, Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations, Cell, 146, 318, 10.1016/j.cell.2011.06.019 · DOI · Paper page
  95. Song, 2015, Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system, Stem Cells Dev., 24, 1053, 10.1089/scd.2014.0347 · DOI
  96. Suda, 2007, Hydrodynamic gene delivery: its principles and applications, Mol. Ther., 15, 2063, 10.1038/sj.mt.6300314 · DOI
  97. Sun, 2013, Transcription activator-like effector nucleases (TALENs): a highly efficient and versatile tool for genome editing, Biotechnol. Bioeng., 110, 1811, 10.1002/bit.24890 · DOI
  98. Sun, 2014, Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs, Biotechnol. Bioeng., 111, 1048, 10.1002/bit.25018 · DOI
  99. Szczepek, 2007, Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases, Nat. Biotechnol., 25, 786, 10.1038/nbt1317 · DOI · Paper page
  100. Takata, 1998, Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells, EMBO J., 17, 5497, 10.1093/emboj/17.18.5497 · DOI · Paper page
  101. Tebas, 2014, Gene editing of CCR5 in autologous CD4+ T cells of persons infected with HIV, N. Engl. J. Med., 370, 901, 10.1056/NEJMoa1300662 · DOI · Paper page
  102. Terns, 2011, CRISPR-based adaptive immune systems, Curr. Opin. Microbiol., 14, 321, 10.1016/j.mib.2011.03.005 · DOI
  103. Thomas, 2003, Progress and problems with the use of viral vectors for gene therapy, Nat. Rev. Genet., 4, 346, 10.1038/nrg1066 · DOI · Paper page
  104. Thomas, 2003, Progress and problems with the use of viral vectors for gene therapy, Nat. Rev. Genet, 4, 346, 10.1038/nrg1066 · DOI · Paper page
  105. Urnov, 2005, Highly efficient endogenous human gene correction using designed zinc-finger nucleases, Nature, 435, 646, 10.1038/nature03556 · DOI
  106. Urnov, 2010, Genome editing with engineered zinc finger nucleases, Nat. Rev. Genet., 11, 636, 10.1038/nrg2842 · DOI · Paper page
  107. van der Oost, 2009, CRISPR-based adaptive and heritable immunity in prokaryotes, Trends Biochem. Sci., 34, 401, 10.1016/j.tibs.2009.05.002 · DOI
  108. van Gent, 2007, Non-homologous end-joining, a sticky affair, Oncogene, 26, 7731, 10.1038/sj.onc.1210871 · DOI
  109. Wah, 1998, Structure of FokI has implications for DNA cleavage, Proc. Natl. Acad. Sci. U. S. A., 95, 10564, 10.1073/pnas.95.18.10564 · DOI
  110. Wilson, 2013, Design and development of artificial zinc finger transcription factors and zinc finger nucleases to the hTERT locus, Mol. Ther. Nucleic Acids, 2, e87, 10.1038/mtna.2013.12 · DOI
  111. Wolfe, 2000, DNA recognition by Cys2His2 zinc finger proteins, Annu. Rev. Biophys. Biomol. Struct., 29, 183, 10.1146/annurev.biophys.29.1.183 · DOI · Paper page
  112. Wright, 2014, TALEN-mediated genome editing: prospects and perspectives, Biochem. J., 462, 15, 10.1042/BJ20140295 · DOI
  113. Wu, 2015, Correction of a genetic disease by CRISPR-Cas9-mediated gene editing in mouse spermatogonial stem cells, Cell Res., 25, 67, 10.1038/cr.2014.160 · DOI · Paper page
  114. Xie, 2014, Seamless gene correction of beta-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac, Genome Res., 24, 1526, 10.1101/gr.173427.114 · DOI · Paper page
  115. Xu, 2013, Targeted myostatin gene editing in multiple mammalian species directed by a single pair of TALE nucleases, Mol. Ther. Nucleic Acids, 2, e112, 10.1038/mtna.2013.39 · DOI
  116. Xu, 1996, Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection, Biochemistry, 35, 5616, 10.1021/bi9602019 · DOI
  117. Xue, 2014, CRISPR-mediated direct mutation of cancer genes in the mouse liver, Nature, 514, 380, 10.1038/nature13589 · DOI · Paper page
  118. Yang, 2013, One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering, Cell, 154, 1370, 10.1016/j.cell.2013.08.022 · DOI · Paper page
  119. Yang, 2014, Targeted and genome-wide sequencing reveal single nucleotide variations impacting specificity of Cas9 in human stem cells, Nat. Commun., 5, 5507, 10.1038/ncomms6507 · DOI
  120. Ye, 2014, Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Delta32 mutation confers resistance to HIV infection, Proc. Natl. Acad. Sci. U. S. A., 111, 9591, 10.1073/pnas.1407473111 · DOI · Paper page
  121. Yin, 2014, Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype, Nat. Biotechnol., 32, 551, 10.1038/nbt.2884 · DOI · Paper page
  122. Yu, 2015, Disruption of human papillomavirus 16 E6 gene by clustered regularly interspaced short palindromic repeat/Cas system in human cervical cancer cells, Onco Targets Ther., 8, 37
  123. Yusa, 2011, Targeted gene correction of alpha1-antitrypsin deficiency in induced pluripotent stem cells, Nature, 478, 391, 10.1038/nature10424 · DOI
  124. Zhen, 2015, Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus, Gene Ther., 22, 404, 10.1038/gt.2015.2 · DOI · Paper page
  125. Zhen, 2014, In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9, Biochem. Biophys. Res. Commun., 450, 1422, 10.1016/j.bbrc.2014.07.014 · DOI · Paper page
  126. Zhu, 2015, The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA, Retrovirology, 12, 22, 10.1186/s12977-015-0150-z · DOI
  127. Zou, 2009, Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells, Cell Stem Cell, 5, 97, 10.1016/j.stem.2009.05.023 · DOI
  128. Zou, 2011, Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting, Blood, 117, 5561, 10.1182/blood-2010-12-328161 · DOI
  129. Zuris, 2014, Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo, Nat. Biotechnol., 33, 73, 10.1038/nbt.3081 · DOI · Paper page

Cited by

Sorted by citations

See all 111

Metadata

Authors
LaFountaine, J. S., Fathe, K., & Smyth, H. D. C.
Venue
International Journal of Pharmaceutics
Publisher
Elsevier BV
Published
2015-10
Volume
494
Issue
1
Pages
180-194
ISSN
0378-5173
DOI
10.1016/j.ijpharm.2015.08.029
Cited by
111
References
32
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review